Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes

Background Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antidiabetic drugs used for treating type 2 diabetes mellitus. While many studies have reported on the cost-effectiveness of DPP-4 inhibitors for treating type 2 diabetes, a systematic review of economic evaluations of DPP-4 inh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics 2015-06, Vol.33 (6), p.581-597
Hauptverfasser:	Geng, Jinsong, Yu, Hao, Mao, Yiwei, Zhang, Peng, Chen, Yingyao
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Cost analysis Cost estimates Cost-Benefit Analysis Diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - economics Diabetes Mellitus, Type 2 - enzymology Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - economics Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Drug therapy Drugs Economic aspects Enzyme inhibitors Health Administration Health Economics Health services Health technology assessment Humans Hypoglycemic agents Inhibitor drugs Insulin Medical care, Cost of Medicine Medicine & Public Health Outcome Assessment (Health Care) Pharmaceutical research Pharmacoeconomics and Health Outcomes Public Health Purchasing power parity Quality of Life Research Studies Systematic Review Testing Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!